自1969年合成的选择性β_2受体兴奋剂—舒喘灵(Salbutomol)问世以来,舒喘灵喷吸疗法已成为临床常用、迅速、有效解除支气管痉挛的方法之一,但儿科应用及报告还不普遍。1991年9月我们对22例中、重型小儿哮喘应用喘乐宁气雾剂,临床和肺功能有明显改善,现将观察结果报告如下。1 临床资料1.1 对象和方法(1)对象:本组22例均系现症住院患儿,年龄5～13岁,平均9.1岁,男17例,女5例,病程1～6 Since the advent of salbutomol, a selective β_2 receptor agonist synthesized in 1969, salbutamol has become one of the most commonly used and rapid bronchospasm regimens in clinical practice. However, pediatric applications and reports Not common. In September 1991, 22 cases of moderate and severe pediatric asthma with asthenia aerosol, clinical and pulmonary function improved significantly, the observations are reported as follows. 1 Clinical data 1.1 Subjects and methods (1) Subjects: The group of 22 cases were all cases of hospitalized children, aged 5 to 13 years, mean 9.1 years, 17 males and 5 females, duration 1 to 6